Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 55,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年11月20日,位于加利福尼亚雷德伍德城,纳斯达克股票代码为ADVM的adverum biotechnologies公司今天宣布,在2024年11月17日,adverum的董事会薪酬委员会授予一名新员工非合格股票期权奖励,以购买55,000股普通股,作为2017年adverum诱因计划的一部分。adverum董事会薪酬委员会根据纳斯达克规则5635(c)(4)批准该奖励,作为对新员工就业的诱因。
The stock option has an exercise price per share equal to $6.86, Adverum's closing trading price on November 15, 2024, and will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and 1/48th of the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Adverum through the applicable vesting dates. The award is subject to the terms and conditions of Adverum's 2017 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
该期权的每股行使价格为6.86美元,与adverum 2024年11月15日收盘交易价格相等,将在四年内解锁,底层股票的25%将在适用解锁开始日期的首个周年解锁,之后每月解锁底层股票余额的1/48,共36个月,前提是新员工在适用解锁日期继续服务于adverum。该奖励受限于adverum 2017年诱因计划的条款和条件,以及涵盖授予的适用奖励协议的条款和条件。
About Adverum Biotechnologies
关于Adverum生物技术公司
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .
adverum biotechnologies（纳斯达克：ADVM）是一家临床阶段公司，旨在将基因治疗确立为高度普遍的眼科疾病的新标准治疗，期望开发出恢复视力和预防失明的功能性疗法。利用其专有的玻璃体内（IVT）平台的能力，adverum正在开发耐用的单次给药疗法，旨在在医生办公室中提供，以消除治疗这些疾病所需的频繁眼内注射。adverum正在评估其新型基因治疗候选药物ixoberogene soroparvovec（Ixo-vec，以前称为ADVm-022），作为一种一次性IVT注射，针对患有新生血管或湿性年龄相关性黄斑变性的患者。此外，通过克服与现有治疗方案相关的挑战，adverum期望能够改变治疗标准，保护视力，并在全球范围内产生深远的社会影响。欲了解更多信息，请访问。
Inquiries:
咨询：
Adverum Investor Relations
Adverum投资者关系
Email: ir@adverum.com
电子邮件:ir@adverum.com
